o-glcnac

OSMI-1 is an O-GlcNAc transferase (OGT) inhibitor (IC50=2.7 μM) that is orally active and cell-permeable. OSMI-1 inhibits protein O-GlcNA acetylation without qualitatively altering cell-surface N- or O- linked glycans.

UDP-3-O-acyl-GlcNAc diammonium functions as a metabolite in E. coli, playing a critical role in the biosynthesis pathway of 3-deoxy-D-manno-octulosonate (KDO) [1].

UDP-3-O-acyl-GlcNAc (UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine) Tris functions as a metabolite in E. coli, participating in the biosynthesis pathway of 3-deoxy-D-manno-octulosonate (KDO) [1].

UDP-3-O-acyl-GlcNAc (UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine), an E. coli metabolite, is involved in the 3-deoxy-D-manno-octulosonate (KDO) biosynthesis pathway [1].

O-GlcNAcase-IN-2 (compound 81) is an orally active, brain-penetrant inhibitor of O-GlcNAcase, demonstrating an IC50 value of 4.93 nM. It has shown potential in elevating protein O-GlcNAcylation levels and promoting phosphorylation of tau (p-Ser199, p-Thr205, p-Ser396) in an OA-impacted SH-SY5Y cell model. Additionally, O-GlcNAcase-IN-2 has been observed to ameliorate cognitive deficits in APP PS1 mice, suggesting its potential utility in combating Alzheimer's disease (AD).

O-GlcNAcase-IN-4 is an inhibitor of O-GlcNAcase. It holds potential for researching neurodegenerative diseases and disorders, including Alzheimer's disease [1].

O-GlcNAcase-IN-1 is a potent and novel inhibitor of O-GlcNAcase(OGA) with an IC 50 value of 46 nM.

OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor (EC50 of 3 μM in cells) that can be used to study OGT inhibition in different human cell lines.

OGT inhibitor 4a is an O-linked n-acetylglucosaminyltransferase (OGT) inhibitor with anticancer activity for the study of autoimmune and neurological disorders.

JNJ-65355394 is an effective O-GlcNAc hydrolase (OGA) inhibitor and an OGA chemical probe.

OSMI-3 is a potent and cell-permeable inhibitor of O-GlcNAc transferase (OGT) for the study of cancer and cardiovascular disease.

N-Acetyl-D-Glucosamine (NAG) is a monosaccharide derivative of glucose. It is released by the action of O-GlcNAcase, in mammalian systems from proteins that have been post-translationally modified with O-GlcNAc.

Thiamet G is a potent, selective O-GlcNAcase inhibitor with Kiof 21 nM, while exhibiting 37, 000-fold selectivity over human lysosomal –hexosaminidase.

OGT-IN-2 is a potent O-GlcNAc transferase (OGT) inhibitor. OGT-IN-2 inhibits sOGT and ncOGT with IC50 values of 30 μM and 53 μM, respectively[1]. OGT-IN-2 can be used for the research of articular diseases[1].

(Rac)-OSMI-1 is a racemate of OSMI-1. OSMI-1 is an inhibitor of O-GlcNAc transferase (OGT) (IC50: 2.7 μM). OSMI-1 inhibits protein O-linked N-acetylglucosaminoglycans (O-GlcNAcylation) in mammalian cell lines and does not qualitatively alter cell surface N- or O-linked glycans.

BZX2 is a novel inhibitor of O-GlcNAc transferase (OGT) activity.

NAG-thiazoline (GlcNAc-thiazoline) is an O-GlcNAcase inhibitor with Ki value of 180 nM. It is active against V. campbellii with MIC value of 0.5 μM.

(Z)-PUGNAc, a potent O-GlcNAcase inhibitor more active than (E)-PUGNAc, removes O-GlcNAc from proteins (peptide O-GlcNAc-β-N-acetylaminoglucosidase) and can be used to increase levels of O-GlcNAc on nuclear and cytoplasmic proteins in vivo.

Histone H2B (108-125) is a peptide fragment of histone H2B that corresponds to amino acid residues 109-126 of the human histone H2B sequence. It contains an N-terminal biotinylated lysine followed by a tryptophan linker. Histone H2B can be modified by addition of an O-linked N-acetylglucosamine (GlcNAc) moiety to the serine residue at position 112, which promotes monoubiquitination of the lysine at position 120.1 Both of these modifications are associated with active transcription. Histone H2B also has lysine residues at positions 108, 116, and 120 that are subject to acetylation.2References1. Fujiki, R., Hashiba, W., Sekine, H., et al. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 480(7378), 557-560 (2011).2. Portela, A., and Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057-1068 (2010). Histone H2B (108-125) is a peptide fragment of histone H2B that corresponds to amino acid residues 109-126 of the human histone H2B sequence. It contains an N-terminal biotinylated lysine followed by a tryptophan linker. Histone H2B can be modified by addition of an O-linked N-acetylglucosamine (GlcNAc) moiety to the serine residue at position 112, which promotes monoubiquitination of the lysine at position 120.1 Both of these modifications are associated with active transcription. Histone H2B also has lysine residues at positions 108, 116, and 120 that are subject to acetylation.2 References1. Fujiki, R., Hashiba, W., Sekine, H., et al. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 480(7378), 557-560 (2011).2. Portela, A., and Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057-1068 (2010).

PG 34 is a structural analogue of OSMI-1 and a weak inhibitor of O-GlcNAc translocase (OGT) with an IC50 value of 68 μM.

2-[(Azidoacety)amino]-2-deoxy-D-galactose targets proteins modified by O-GlcNAc. By detecting and localizing these proteins, 2-[(Azidoacety)amino]-2-deoxy-D-galactose serves as a chemical tag for tracking glycoconjugate metabolism within cells.

BZX1 is an O-Iinked N-acetylglucosaminyltransferase inhibitor, which can be used to study abnormal cell differentiation and cartilage degeneration.

UDP-GlcNAc Disodium Salt (UDP-α-D-N-Acetylglucosamine Disodium Salt) is a nucleotide sugar synthesized from glucose through the hexosamine biosynthetic pathway (HBP).